Damian Mojsak
Overview
Explore the profile of Damian Mojsak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debczynski M, Mojsak D, Minarowski L, Maciejewska M, Mroz R, Lisowski P
Adv Med Sci
. 2025 Feb;
PMID: 39952431
No abstract available.
2.
Debczynski M, Gorrieri G, Mojsak D, Guida F, Zara F, Scudieri P
Biomolecules
. 2023 Oct;
13(10).
PMID: 37892136
encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways,...
3.
Debczynski M, Mojsak D, Tamburro S, Baldassari S, Musante I, Casciaro R, et al.
Stem Cell Res
. 2023 Oct;
72:103232.
PMID: 37865062
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is a chloride channel defective in cystic fibrosis (CF). Several CFTR mutations are causative of CF, among which G542X is a nonsense mutation introducing...
4.
Debczynski M, Mojsak D, Minarowski L, Maciejewska M, Lisowski P, Mroz R
Adv Med Sci
. 2023 Mar;
68(1):111-120.
PMID: 36917892
Cystic fibrosis (CF) is an autosomal recessive disease caused by defects in the CF transmembrane conductance regulator (CFTR) protein. Due to the genetic nature of the disease, interventions in the...
5.
Mojsak D, Debczynski M, Kuklinska B, Minarowski L, Kasiukiewicz A, Moniuszko-Malinowska A, et al.
Int J Environ Res Public Health
. 2023 Jan;
20(2).
PMID: 36674340
The COVID-19 pandemic poses a challenge to health systems worldwide. Limiting healthcare availability may delay early diagnosis and worsen the treatment effects of various diseases, including oncological diseases. We analyzed...
6.
Debczynski M, Mojsak D, Kuklinska B, Mroz R
Am J Case Rep
. 2022 Aug;
23:e936536.
PMID: 35949112
BACKGROUND Atezolizumab is an immune checkpoint inhibitor used as first-line treatment with carboplatin and etoposide chemotherapy for advanced small cell lung cancer. Immunochemotherapy treatment decisions can be affected by patients'...
7.
Mojsak D, Debczynski M, Kuklinska B, Moniuszko-Malinowska A, Mroz R
Am J Case Rep
. 2022 Jun;
23:e936420.
PMID: 35648729
BACKGROUND Advanced non-small cell lung cancer has poor prognosis and low survival. Immunotherapy with the use of immune checkpoint inhibitors is a relatively new method of treatment that offers a...
8.
Mojsak D, Kuklinska B, Minarowski L, Mroz R
Adv Med Sci
. 2021 Jul;
66(2):381-387.
PMID: 34315013
Background: Patients with Eastern Cooperative Oncology Group Performance Status 2 (ECOG PS 2) are not included in most randomized clinical trials and registry studies. Nevertheless, immune checkpoint inhibitors are registered...
9.
Mojsak D, Kuklinska B, Debczynski M, Mroz R
Contemp Oncol (Pozn)
. 2021 Apr;
25(1):53-56.
PMID: 33911982
Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based...
10.
Jankowski M, Minarowski L, Mroz R, Guziejko K, Mojsak D, Poznanski M, et al.
Adv Med Sci
. 2020 Sep;
65(2):437-441.
PMID: 32979795
Purpose: Electronic cigarette (e-cigarette) use is one of the most popular alternatives to conventional cigarette smoking. This study aimed to investigate the prevalence of cigarette and e-cigarette use among university...